EA202190864A1 - Способы выделения и размножения клеток - Google Patents

Способы выделения и размножения клеток

Info

Publication number
EA202190864A1
EA202190864A1 EA202190864A EA202190864A EA202190864A1 EA 202190864 A1 EA202190864 A1 EA 202190864A1 EA 202190864 A EA202190864 A EA 202190864A EA 202190864 A EA202190864 A EA 202190864A EA 202190864 A1 EA202190864 A1 EA 202190864A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
methods
hematopoietic tissue
reproduction
isolation
Prior art date
Application number
EA202190864A
Other languages
English (en)
Russian (ru)
Inventor
Шристи Бхандари
Сэмюэл Флоренс
Эндрю Хаттон
Луиза Матиас
Оливер Нуссбаумер
Калле Содерстрём
Марк Уден
Original Assignee
Гаммадельта Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гаммадельта Терапьютикс Лимитед filed Critical Гаммадельта Терапьютикс Лимитед
Publication of EA202190864A1 publication Critical patent/EA202190864A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/24—Gas permeable parts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Clinical Laboratory Science (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA202190864A 2018-11-08 2019-11-08 Способы выделения и размножения клеток EA202190864A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1818243.6A GB201818243D0 (en) 2018-11-08 2018-11-08 Methods for isolating and expanding cells
PCT/GB2019/053166 WO2020095059A1 (en) 2018-11-08 2019-11-08 Methods for isolating and expanding cells

Publications (1)

Publication Number Publication Date
EA202190864A1 true EA202190864A1 (ru) 2021-09-14

Family

ID=64739360

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190864A EA202190864A1 (ru) 2018-11-08 2019-11-08 Способы выделения и размножения клеток

Country Status (14)

Country Link
US (2) US12460180B2 (cg-RX-API-DMAC7.html)
EP (1) EP3877510A1 (cg-RX-API-DMAC7.html)
JP (2) JP7665513B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210111747A (cg-RX-API-DMAC7.html)
CN (1) CN113423821A (cg-RX-API-DMAC7.html)
AU (2) AU2019374489B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008166A2 (cg-RX-API-DMAC7.html)
CA (1) CA3117913A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190864A1 (cg-RX-API-DMAC7.html)
GB (1) GB201818243D0 (cg-RX-API-DMAC7.html)
IL (1) IL282901A (cg-RX-API-DMAC7.html)
MX (1) MX2021005480A (cg-RX-API-DMAC7.html)
PH (1) PH12021551038A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020095059A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
JP2022545196A (ja) 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗tcrデルタ可変1抗体の治療的使用
CA3148588A1 (en) 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations
GB202002581D0 (en) 2020-02-24 2020-04-08 Gammadelta Therapeutics Ltd Novel antibodies
ES2943063T5 (en) 2020-08-14 2026-05-05 Gammadelta Therapeutics Ltd Multispecific anti-tcr delta variable 1 antibodies
KR20230160253A (ko) 2021-02-17 2023-11-23 감마델타 테라퓨틱스 엘티디 항-tcr 델타 가변 1 항체
GB202105113D0 (en) 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
CA3228168A1 (en) 2021-08-03 2023-02-09 Gammadelta Therapeutics Ltd Engineering of gamma delta t cells and compositions thereof
GB202204926D0 (en) * 2022-04-04 2022-05-18 Gammadelta Therapeutics Ltd Method for expanding gammadelta T cells
PE20242341A1 (es) 2022-04-04 2024-12-12 Gammadelta Therapeutics Ltd Blindaje genetico novedoso
WO2025017531A1 (en) * 2023-07-20 2025-01-23 Takeda Pharmaceutical Company Limited Grid-free methods for making gamma delta t cells

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US7078034B2 (en) 1999-01-28 2006-07-18 Palmetto Health Alliance In vitro activated γ δ lymphocytes
CN101120083B (zh) 2003-10-08 2013-03-27 威尔森沃尔夫制造公司 利用透气性材料进行细胞培养的方法及装置
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
JP4659785B2 (ja) * 2007-06-15 2011-03-30 トヨタ自動車株式会社 内燃機関の燃料噴射制御装置
US8529883B2 (en) * 2010-05-07 2013-09-10 Fibrocell Technologies, Inc. Dosage unit formulations of autologous dermal fibroblasts
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP2710123B1 (en) 2011-05-19 2017-07-12 Instituto de Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
US9907820B2 (en) 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
UA123821C2 (uk) 2014-06-11 2021-06-09 Полібіосепт Гмбх Композиція для експансії лімфоцитів in vitro
RU2756247C2 (ru) 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
JP6799895B2 (ja) 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. TCRγδ+T細胞の生産方法
CN108473958A (zh) * 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
TWI826360B (zh) 2016-11-17 2023-12-21 美商艾歐凡斯生物治療公司 殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
AU2018205234B2 (en) 2017-01-06 2024-09-19 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
KR20210111746A (ko) 2018-11-08 2021-09-13 감마델타 테라퓨틱스 리미티드 세포를 단리 및 증식하는 방법

Also Published As

Publication number Publication date
JP2022506841A (ja) 2022-01-17
BR112021008166A2 (pt) 2021-08-03
WO2020095059A1 (en) 2020-05-14
CN113423821A (zh) 2021-09-21
AU2026204440A1 (en) 2026-06-25
AU2019374489B2 (en) 2026-04-02
KR20210111747A (ko) 2021-09-13
MX2021005480A (es) 2021-11-04
US20260201331A1 (en) 2026-07-16
AU2019374489A1 (en) 2021-05-27
GB201818243D0 (en) 2018-12-26
US20220010276A1 (en) 2022-01-13
PH12021551038A1 (en) 2022-01-03
CA3117913A1 (en) 2020-05-14
JP7665513B2 (ja) 2025-04-21
US12460180B2 (en) 2025-11-04
EP3877510A1 (en) 2021-09-15
IL282901A (en) 2021-06-30
JP2025106453A (ja) 2025-07-15

Similar Documents

Publication Publication Date Title
MX2021005480A (es) Metodos para aislar y expandir celulas.
EA202190871A1 (ru) Способы выделения и размножения клеток
MX2016016251A (es) Expansion de linfocitos con composicion de citocinas para inmunoterapia celular activa.
CN103865876B (zh) 一种肿瘤细胞原代培养的方法
RU2011121630A (ru) Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
MY177268A (en) Medium system and method for ex vivo expansion of nk cells
Najar et al. Bone marrow mesenchymal stromal cells induce proliferative, cytokinic and molecular changes during the T cell response: the importance of the IL-10/CD210 axis
PE20221185A1 (es) Metodos para mejorar el crecimiento celular con proteinas especificas de especie o genero y sus aplicaciones
MX2019013184A (es) Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso.
JP2022506841A5 (cg-RX-API-DMAC7.html)
ATE459652T1 (de) Verfahren zur herstellung von antikörpern
EA201890121A1 (ru) Способ пролиферации естественных клеток-киллеров и композиции для пролиферации естественных клеток-киллеров
SA520412566B1 (ar) طريقة إنتاج الخلايا القاتلة الطبيعية وتركيبة لعلاج السرطان
EA202192714A1 (ru) Система и способ извлечения и криоконсервации костного мозга
WO2019036043A3 (en) METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
PL439808A1 (pl) Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał
JP2013537187A5 (cg-RX-API-DMAC7.html)
BR112022004562A2 (pt) Método de seleção de doador universal para identificar doadores de células nk
MX2024004122A (es) Células citolíticas (asesinas) naturales y métodos de uso de las mismas.
EA202091349A1 (ru) Способы культивирования клеток
RU2014148172A (ru) Способы индукции антигенспецифических регуляторных т-клеток
Lee et al. Generation of cell-derived matrices that support human NK cell migration and differentiation
Zhao et al. Involvement of CD26 in Differentiation and Functions of Th1 and Th17 Subpopulations of T Lymphocytes
ATE465243T1 (de) Verfahren zur isolierung und kultivierung aus kryokonserviertem nabelschnurblut gewonnener mesenchymaler stammzellen
MX2021013005A (es) Metodos de fabricacion de celulas car-t alogenicas.